Article Per Year (5 Year)
p-Index From 2021 - 2026
4.06
P-Index
This Author published in this journals
All Journal Jurnal Kesehatan Andalas Buletin Ilmiah Nagari Membangun Majalah Kedokteran Andalas Bioscientia Medicina : Journal of Biomedicine and Translational Research Health and Medical Journal Bioscientia Medicina : Journal of Biomedicine and Translational Research Jurnal Ilmu Kesehatan Indonesia (JIKSI) The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy Ranah Research : Journal of Multidisciplinary Research and Development Jurnal Kesehatan Masyarakat Indonesia (JKMI)
Saptino Miro
Fakultas Kedokteran Universitas Andalas
Agriculture, Biological Sciences & Forestry Humanities Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Civil Engineering, Building, Construction & Architecture Dentistry Economics, Econometrics & Finance Education Engineering Environmental Science Health Professions Immunology & microbiology Languange, Linguistic, Communication & Media Law, Crime, Criminology & Criminal Justice Medicine & Pharmacology Neuroscience Nursing Public Health Social Sciences Transportation Veterinary Other

Published : 36 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 36 Documents
Search

 1   2   3   4 
Diagnosis and Current Management of Hepatocellular Carcinoma Satria, Rivo Armanda; Saptino Miro
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 8 No. 3 (2024): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v8i3.945

Abstract

Hepatocellular carcinoma (HCC) is a primary malignant liver tumor originating from hepatocytes which has a very poor prognosis and is ranked the sixth most common cancer disease in the world and is ranked third in deaths caused by cancer worldwide. Symptoms of underlying liver diseases such as hepatitis and cirrhosis often disguise the diagnosis of HCC so that most cases are discovered at an advanced stage. The examination modalities commonly used in surveillance are liver ultrasound (USG) examination and measurement of alpha levels fetoprotein (AFP) with sensitivity diagnostic up to 90%. Non-invasive imaging plays an important role in objective recognition and staging enforcement diagnosis as early as possible so that the patient's prognosis is better. Treatment for early-stage HCC can be given through curative therapy such as resection, liver transplantation, and local ablation, but disease at an advanced stage causes limited options in management where governance The current focus is on systemic therapy with a focus on a combination strategy of immunotherapy or a combination of targeted therapy with immunotherapy as the first line.
Demographic, Clinical, and Treatment Factors That Affect the Five Years Survival of Thyroid Cancer Patients Alika Ristama Nigandiva; Daan Khambr; Saptino Miro; Novita Ariani; Rony Rustam; Dina Arfiani Rusjdi
Jurnal Kesehatan Masyarakat Indonesia (JKMI) Vol. 1 No. 3 (2024): April
Publisher : Publikasi Inspirasi Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.62017/jkmi.v1i3.1018

Abstract

Thyroid cancer is the most common malignancy of the endocrine glands, the incidence of thyroid cancer in Indonesia ranks ninth after other types of cancer, it is known that the survival rate of thyroid cancer is better when compared to other types of cancer because thyroid cancer has a slow growth rate. Several demographic factors such as age and gender, clinical factors and treatments factors can affect the survival rate of thyroid cancer patients. This study was conducted to analyze the influence of demographic, clinical, and management factors on thyroid cancer survival rates at Dr. M. Djamil Padang Hospital. This study is an observational analytic study with a retrospective cross-sectional design. Sampling was done by total sampling technique. Data collection is done through patient medical record data. The results showed a five-year survival rate for thyroid cancer of 86.7%. Age, histopathological type, metastases, tumor extension, and management were significantly related to survival (p=0.013) (p=0.000), (p=0.001), (p=0.000) and (p=0.001).  Factors that have a significant relationship with survival rate are age, histopathological type, tumor extension, treatment, and metastases, and those that most influence survival rate are non-operative management and regional extension
Diagnosis and Current Management of Hepatocellular Carcinoma Satria, Rivo Armanda; Saptino Miro
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 8 No. 3 (2024): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v8i3.945

Abstract

Hepatocellular carcinoma (HCC) is a primary malignant liver tumor originating from hepatocytes which has a very poor prognosis and is ranked the sixth most common cancer disease in the world and is ranked third in deaths caused by cancer worldwide. Symptoms of underlying liver diseases such as hepatitis and cirrhosis often disguise the diagnosis of HCC so that most cases are discovered at an advanced stage. The examination modalities commonly used in surveillance are liver ultrasound (USG) examination and measurement of alpha levels fetoprotein (AFP) with sensitivity diagnostic up to 90%. Non-invasive imaging plays an important role in objective recognition and staging enforcement diagnosis as early as possible so that the patient's prognosis is better. Treatment for early-stage HCC can be given through curative therapy such as resection, liver transplantation, and local ablation, but disease at an advanced stage causes limited options in management where governance The current focus is on systemic therapy with a focus on a combination strategy of immunotherapy or a combination of targeted therapy with immunotherapy as the first line.
Management of Thrombocytopenia with Partial Splenic Embolization in Liver Cirrhosis Putri, Septia Harma; Arnelis; Saptino Miro
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 8 No. 6 (2024): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v8i6.1015

Abstract

Thrombocytopenia is a frequent complication in patients with cirrhosis. Thrombocytopenia is generally divided into mild, moderate, and severe thrombocytopenia. Thrombocytopenia in liver cirrhosis not only increases the risk of bleeding during surgery but can also have an impact on patient management, such as liver biopsy, administration of antiviral therapy, and postponement of elective surgery. The pathophysiology of thrombocytopenia in chronic liver disease can be caused by decreased platelet production, sequestration in the spleen, and increased platelet destruction. Partial splenic embolization (PSE) is one option for treating thrombocytopenia in chronic liver disease. PSE is an effective procedure in treating complications associated with hypersplenism and portal hypertension, such as esophageal varices, pancytopenia, portal hypertensive gastropathy and ascites.
Argon Plasma Coagulation for Proctitis: A Meta-Analysis Fisca Syofi Arrasyi; Saptino Miro
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 9 No. 1 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v9i1.1156

Abstract

Background: Proctitis, encompassing various etiologies, significantly diminishes patient quality of life. Argon plasma coagulation (APC) has emerged as a potential therapeutic modality, yet its efficacy and safety profile remain to be fully elucidated. This meta-analysis aimed to rigorously evaluate the effectiveness and safety of APC across diverse proctitis subtypes. Methods: A comprehensive search of PubMed, Embase, and the Cochrane Library databases was conducted, spanning 2013 to 2023, to identify pertinent studies. Randomized controlled trials (RCTs) and observational studies comparing APC with alternative treatments or placebo in proctitis management were included. The primary outcome was clinical improvement, defined as symptom reduction or amelioration of endoscopic findings. Secondary outcomes encompassed adverse events and quality of life metrics. Results: A total of 15 studies (5 RCTs and 10 observational studies) encompassing 2042 patients met the inclusion criteria. APC demonstrated a significant association with clinical response improvement compared to other treatments or placebo (OR 2.58, 95% CI 2.14-3.12, p<0.001). Subgroup analysis revealed APC's efficacy in both radiation-induced and non-radiation-induced proctitis. Adverse event incidence was comparable between APC and other treatments, with no significant differences in severe complications. Conclusion: APC appears to be an effective and safe therapeutic option for various proctitis subtypes, warranting consideration in clinical practice.
Pharmacological and Interventional Approaches to Ascites Management in Cirrhosis: A Meta-Analysis Annisa Ul Husni; Saptino Miro
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 9 No. 3 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v9i3.1231

Abstract

Background: Ascites, a common complication of cirrhosis, significantly impacts patient morbidity and mortality. This meta-analysis evaluated the efficacy and safety of various pharmacological and interventional approaches for ascites management in patients with cirrhosis. Methods: A systematic search of PubMed, Embase, and Cochrane Library databases was conducted from January 2013 to December 2024, identifying randomized controlled trials (RCTs) comparing different pharmacological agents (diuretics, albumin, vasopressin receptor antagonists) and interventional procedures (large-volume paracentesis, transjugular intrahepatic portosystemic shunt [TIPS]) in cirrhotic patients with ascites. The primary outcome was complete ascites resolution. Secondary outcomes included time to ascites recurrence, adverse events, and mortality. A random-effects model was used to pool data, and heterogeneity was assessed using the I² statistic. Results: Twelve RCTs (n=2848 patients) met the inclusion criteria. Diuretics plus albumin was superior to diuretics alone in achieving complete ascites resolution (OR 2.18, 95% CI 1.65-2.88, p<0.001; I²=38%). Vasopressin receptor antagonists were comparable to diuretics plus albumin in terms of ascites resolution (OR 1.09, 95% CI 0.88-1.35, p=0.42; I²=12%) but associated with a lower incidence of hyponatremia (OR 0.52, 95% CI 0.35-0.78, p=0.002; I²=23%). Large-volume paracentesis was more effective than repeated small-volume paracentesis for ascites control (OR 1.75, 95% CI 1.31-2.34, p<0.001; I²=41%). TIPS was associated with a higher rate of complete ascites resolution compared to large-volume paracentesis (OR 2.45, 95% CI 1.78-3.38, p<0001; I²=35%) but a higher risk of hepatic encephalopathy (OR 2.21, 95% CI 1.48-3.30, p<0.001; I²=15%). Albumin reduced mortality in patients undergoing large-volume paracentesis (OR 0.68, 95% CI 0.49-0.94, p=0.02; I²=0%). Conclusion: This meta-analysis supports the use of diuretics plus albumin, vasopressin receptor antagonists, large-volume paracentesis, and TIPS for ascites management in cirrhosis, with the choice of therapy individualized based on patient characteristics, ascites severity, and the risk of complications.
Co-Authors Abd. Rasyid Syamsuri Abdul Alim Rahimi Ade Asyari Afida Razuna Ave Afifah Amatullah Alexander Kam Alexander Kam Alika Ristama Nigandiva Almurdi Almurdi Andani Eka Putra Andry Kurniawan Andry Kurniawan Andry Kurniawan Andry Kurniawan Andry Kurniawan Angela Lovena Annisa Ul Husni Arina Widya Murni Arnelis Arnelis Arnelis Arnelis Arnelis Arnelis Arnelis Arnelis Arnelis Asrining Tyas Asterina Asterina Bayu Gemilang Daan Khambr Deka Viotra Delmi Sulastri Detty Iryani Dia Rofinda, Zelly Dia Dian Pertiwi Diego Lesgenia Dina Arfiani Rusjdi Dinda Aprillia Dinda Aprillia Dwi Yulia Dwi Yulia Dwitya Elvira, Dwitya Efrida Efrida Eka Kurniawan Elmatris Sy Emil Prasetyo Muhammad Endrinaldi Eti Yerizel Eva Decroli Fadhil Alfino Azmi Fauzar Fauzar Fauzar Fauzar Fisca Syofi Arrasyi Hendra Saputra Husna Yetti Jersivindo Ranazeri Mefri Yanni Nada Utami Prahastiwi Najirman Najirman Nandia Rizkita Nasrul Zubir Nasrul Zubir Nasrul Zubir Nasrul Zubir Novita Ariani Putri Reno Indrisia Putri Wahyuni Putri, Septia Harma R. Ifan Arief Fahrurozi Rahmatini . Raveinal Raveinal RAVEINAL RAVEINAL Restu Susanti Rikarni Rikarni Rivani Sintia Suratman Rivo Armanda Satria Rony Rustam Roza Kurniati Roza Kurniati Roza Mulyana Rudy Afriant Sherly Febrina Suri Hanifa Efendi Vella Paraditha Vesri Yoga Vesri Yoga Yanwirasti Yanwirasti Yustini Alioes Zaki Ihsan Kamil